臨床婦人科産科76巻10号

2022年10月発行

今月の臨床 女性医学から読み解くメタボリック症候群―専門医のための必須知識 最新治療編

肥満に対する最新治療―抗肥満薬の現状と未来

著者： 上野浩晶¹

所属機関： ¹宮崎大学医学部内科学講座血液・糖尿病・内分泌内科学分野

ページ範囲：P.1028 - P.1034

●内因性の摂食調節ペプチドを応用した抗肥満薬が多数開発中である．

●半減期を長くした週1回投与製剤や，皮下注射ではなく経口投与が可能な製剤も開発されている．

●複数の摂食調節ペプチドの構造を併せ持ち，より強力な摂食抑制作用を示す薬剤も臨床応用されつつある．

参考文献

1）Vasandani C, et al : Efficacy and safety of metreleptin therapy in patients with type 1 diabetes : a pilot study. Diabetes Care 40 : 694-697, 2017

2）Moon HS, et al : Efficacy of metreleptin in obese patients with type 2 diabetes : cellular and molecular pathways underlying leptin tolerance. Diabetes 60 : 1647-1656, 2011

3）Shetty GK, et al : Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol 165 : 249-254, 2011

4）Hollander P, et al : Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12 : 661-668, 2004

5）Smith SR, et al : Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects : a 6-wk translational research study. Am J Physiol Endocrinol Metab 293 : E620-E627, 2007

6）Qiao YC, et al : Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus : a systematic review and meta-analysis. Oncotarget 8 : 66504-66515, 2017

7）Ravussin E, et al : Enhanced weight loss with pramlintide/metreleptin : an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17 : 1736-1743, 2009

8）Lau DCW, et al : Once-weekly cagrilintide for weight management in people with overweight and obesity : a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398 : 2160-2172, 2021

9）Pi-Sunyer X, et al : A randomized, controlled trial of 3.0mg of liraglutide in weight management. N Engl J Med 373 : 11-22, 2015

10）Araki E, et al : Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes : a post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes Obes Metab 23 : 2785-2794, 2021

11）Husain M, et al : Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381 : 841-851, 2019

12）Killion EA, et al : Chronic glucose-dependent insulinotropic polypeptide receptor（GIPR）agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat Commun 11 : 4981, 2020

13）Adriaenssens AE, et al : Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 30 : 987-996. e6, 2019

14）Frias JP, et al : The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26 : 343-352. e2, 2017

15）Del Prato S, et al : Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk（SURPASS-4）: a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398 : 1811-1824, 2021

16）Schiavon M, et al : Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab 23 : 1795-1805, 2021

17）Asano M, et al : Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes. Diabetes Obes Metab 23 : 1859-1867, 2021

18）Nahra R, et al : Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes : a 54-week randomized hase 2b study. Diabetes Care 44 : 1433-1442, 2021

19）Ji L, et al : IBI362（LY3305677）, a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity : a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine 39 : 101088, 2021

20）Finan B, et al : A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21 : 27-36, 2015